Sarcoma

Research Article

Treatment of Recurrent or Metastatic Uterine Adenosarcoma

Table 2

Treatment characteristics on recurrence with 1st, 2nd, and 3rd line chemotherapy for recurrent or metastatic disease.
Treatment on 1st recurrence
 Surgery alone13 (16.7%)
 Surgery + radiation8 (10.3%)
 Radiation alone1 (1.3%)
 Surgery + chemotherapy19 (24.3%)
 Chemotherapy alone18 (23.1%)
 Surgery + chemotherapy + radiation5 (6.4%)
 Chemotherapy + radiation1 (1.3%)
 Hormonal therapy alone3 (3.8%)
 None1 (1.3%)
 Unknown9 (11.6%)
Treatment on 2nd recurrence
 Surgery alone11 (14.1%)
 Surgery + radiation2 (2.6%)
 Surgery + chemotherapy6 (7.7%)
 Chemotherapy alone11 (14.1%)
 Chemotherapy + radiation2 (2.6%)
 Unknown17 (21.8%)
 Did not obtain NED after 1st recurrence29 (37.2%)
1st line chemotherapy additional treatments
 Chemotherapy alone30 (50.9%)
 Chemotherapy + surgery20 (33.9%)
 Chemotherapy + radiation2 (3.4%)
 Chemotherapy + radiation + surgery4 (6.8%)
 Chemotherapy + hormonal therapy1 (1.7%)
 Chemotherapy + surgery + hormonal therapy2 (3.4%)
 Chemotherapy given for residual disease after initial treatment3 (5.1%)
 Chemotherapy given for 1st recurrence40 (67.8%)
 Chemotherapy given for 2nd recurrence10 (16.9%)
 Chemotherapy given for 3rd recurrence2 (3.4%)
 Chemotherapy given for 4th recurrence2 (3.4%)
 Chemotherapy given for >4th recurrence1 (1.7%)
 Recurrence chemotherapy given for unknown1 (1.7%)
1st line chemotherapy regimens
 Doxorubicin based28 (47.5%)
  Doxorubicin alone+4
  AI (doxorubicin/ifosfamide)9
  VAI (vincristine/doxorubicin/ifosfamide)1
  ADIC (doxorubicin/dacarbazine)3
  MAID (doxorubicin/ifosfamide/dacarbazine)1
  Other doxorubicin based10
 Gemcitabine/docetaxel14 (23.7%)
 Platinum based12 (20.3%)
 Other (ifosfamide/paclitaxel (2), paclitaxel, gemcitabine)4 (6.8%)
 Unknown1 (1.7%)
2nd line chemotherapy regimens
 Doxorubicin based6 (25.0%)
  Doxorubicin alone+3
  AI (doxorubicin/ifosfamide)3
 Gemcitabine/docetaxel9 (37.5%)
 Platinum based (cisplatin/ifosfamide in one patient)4 (16.7%)
 Other (ifosfamide, paclitaxel, paclitaxel/bevacizumab, irinotecan/dacarbazine, trabectedin)5 (20.8%)
3rd line chemotherapy regimens
 Doxorubicin based4 (36.4%)
  Doxorubicin alone2
  AI (doxorubicin/ifosfamide)1
  ADIC (doxorubicin/dacarbazine)1
 Platinum based2 (18.2%)
 Other (ifosfamide (2), paclitaxel, I/E++, TMZ+++)5 (45.5%)
Chemotherapy dosing: gemcitabine 675 to 900 mg/m2, docetaxel 75 to 100 mg/m2, vincristine 2 mg, doxorubicin 60 to 75 mg/m2, ifosfamide 7.5 to 10 gm/m2, and dacarbazine 750 to 1000 mg/m2; doxorubicin/cyclophosphamide/cisplatin (1), low-dose doxorubicin/ifosfamide (50 mg/m2, 2.4 gm/m2) (1), doxorubicin/cisplatin (1), vincristine/doxorubicin/cyclophosphamide (1), doxorubicin/cisplatin/paclitaxel (1), doxorubicin/dacarbazine/cyclophosphamide (3), doxorubicin/carboplatin (1), and vincristine/doxorubicin/cyclophosphamide/dacarbazine (1); carboplatin/docetaxel (2), bleomycin/etoposide/cisplatin (2), carboplatin/paclitaxel (4), cisplatin with weekly radiation (2), carboplatin/paclitaxel/bevacizumab (1), and carboplatin/cyclophosphamide (1); carboplatin/docetaxel (1), carboplatin/paclitaxel (1), cisplatin/ifosfamide (1), and carboplatin/gemcitabine (1); carboplatin/gemcitabine (1) and cisplatin/gemcitabine (1); +one patient had liposomal doxorubicin; ++ifosfamide/etoposide; +++temozolomide.